Acorn Capital Advisors, LLC

Acorn Capital Advisors, LLC, established in 2017 by Anders Hove, specializes in providing investment advisory services for private capital through pooled investment vehicles, focusing on the biopharmaceutical sector. The firm's investment strategy aims to exploit valuation inefficiencies in the healthcare small cap public/private equity sector. Acorn manages approximately $239 million in private fund client assets on a discretionary basis as of December 31, 2024. Management fees are typically 2.0% of aggregate Capital Commitments, reducing by 0.10 percentage points annually. Acorn may earn performance-based compensation through carried interest in profits. The firm follows a non-consensus, value-centric methodology supported by fundamental research and proprietary financial and clinical investigation. Acorn discloses potential conflicts of interest due to its relationship with the General Partner of the funds. The firm exercises discretion in managing client assets, casting proxy votes in the best interests of clients. Acorn does not have any financial conditions impairing its ability to meet commitments. The firm does not have any disciplinary matters, and it does not participate in soft dollar arrangements. Clients receive quarterly unaudited financial statements and annual audited financial statements. Acorn does not receive economic benefits from third parties for advice rendered to clients. The firm may have custody of client funds and securities and provides investment advisory services on a discretionary basis.